Cancer Research Cancer Research Funding Available Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitman, S. P.
Right arrow Articles by Caligiuri, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitman, S. P.
Right arrow Articles by Caligiuri, M. A.
[Cancer Research 61, 7233-7239, October 1, 2001]
© 2001 American Association for Cancer Research

Immunology

Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3

A Cancer and Leukemia Group B Study1

Susan P. Whitman, Kellie J. Archer, Lan Feng, Claudia Baldus, Brian Becknell, Brian D. Carlson, Andrew J. Carroll, Krzysztof Mrózek, James W. Vardiman, Stephen L. George, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield and Michael A. Caligiuri2

The Ohio State University, Columbus, Ohio 43210 [S. P. W., K. J. A., L. F., C. B., B. B., B. D. C., K. M., C. D. B., M. A. C.]; The Cancer and Leukemia Group B Statistical Center, Durham, North Carolina 27710 [K. J. A., S. L. G.]; University of Alabama, Birmingham, Alabama 35249 [A. J. C.]; University of Chicago, Chicago, Illinois 60637 [J. W. V., R. A. L.]; and North Shore University Hospital, Manhasset, New York 11030 [J. E. K.]

The FLT3 gene is mutated by an internal tandem duplication (ITD) in 20–25% of adults with acute myeloid leukemia (AML). We studied 82 adults <60 years of age with primary AML and normal cytogenetics, who received uniform high-dose therapy and found FLT3 ITD in 23 (28%) patients. When the 23 FLT3 ITD+ cases were compared with the 59 cases with wild-type (WT) FLT3, disease-free survival (DFS) was inferior (P = 0.03), yet overall survival (OS) was not different (P = 0.14). However, 8 (35%) of 23 FLT3 ITD/+ cases also lacked a FLT3 WT allele (FLT3ITD-R) as determined by PCR and loss of heterozygosity. Thus, three genotypic groups were identified: normal FLT3WT/WT, heterozygous FLT3ITD/WT, and hemizygous FLT3ITD/-. DFS and OS were significantly inferior for patients with FLT3ITD/- (P = 0.0017 and P = 0.0014, respectively). Although DFS and OS for FLT3WT/WT and FLT3ITD/WT groups did not differ (P = 0.32 and P = 0.98, respectively), OS of the FLT3ITD/- group was worse than the FLT3WT/WT (P = 0.0005) and FLT3ITD/WT (P = 0.008) groups. We propose a model in which FLT3ITD/- represents a dominant positive, gain-of-function mutation providing AML cells with a greater growth advantage compared with cells having the FLT3WT/WT or FLT3ITD/WT genotypes. In conclusion, we have identified the FLT3ITD/- genotype as an adverse prognostic factor in de novo AML with normal cytogenetics. A poor prognosis of the relatively young FLT3ITD/- adults (median age, 37 years), despite treatment with current dose-intensive regimens, suggests that new treatment modalities, such as therapy with a FLT3 tyrosine kinase inhibitor, are clearly needed for this group of patients.




This article has been cited by other articles:


Home page
 BloodHome page
S. Kayser, R. F. Schlenk, M. C. Londono, F. Breitenbuecher, K. Wittke, J. Du, S. Groner, D. Spath, J. Krauter, A. Ganser, et al.
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Blood, September 17, 2009; 114(12): 2386 - 2392.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Langer, G. Marcucci, K. B. Holland, M. D. Radmacher, K. Maharry, P. Paschka, S. P. Whitman, K. Mrozek, C. D. Baldus, R. Vij, et al.
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
J. Clin. Oncol., July 1, 2009; 27(19): 3198 - 3204.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Meshinchi and F. R. Appelbaum
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Clin. Cancer Res., July 1, 2009; 15(13): 4263 - 4269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Dunbar, L. P. Gondek, C. L. O'Keefe, H. Makishima, M. S. Rataul, H. Szpurka, M. A. Sekeres, X. F. Wang, M. A. McDevitt, and J. P. Maciejewski
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Cancer Res., December 15, 2008; 68(24): 10349 - 10357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Virappane, R. Gale, R. Hills, I. Kakkas, K. Summers, J. Stevens, C. Allen, C. Green, H. Quentmeier, H. Drexler, et al.
Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
J. Clin. Oncol., November 20, 2008; 26(33): 5429 - 5435.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, C.-G. Liu, et al.
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
J. Clin. Oncol., November 1, 2008; 26(31): 5078 - 5087.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Radich
Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?
J. Clin. Oncol., October 1, 2008; 26(28): 4539 - 4541.
[Full Text] [PDF]

Home page
 BloodHome page
J. P. Maciejewski and G. J. Mufti
Whole genome scanning as a cytogenetic tool in hematologic malignancies
Blood, August 15, 2008; 112(4): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Raghavan, L.-L. Smith, D. M. Lillington, T. Chaplin, I. Kakkas, G. Molloy, C. Chelala, J.-B. Cazier, J. D. Cavenagh, J. Fitzgibbon, et al.
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
Blood, August 1, 2008; 112(3): 814 - 821.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. J. Mead, R. E. Gale, R. K. Hills, M. Gupta, B. D. Young, A. K. Burnett, and D. C. Linch
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease
Blood, July 15, 2008; 112(2): 444 - 445.
[Full Text] [PDF]

Home page
 haematolHome page
K. Dohner and H. Dohner
Molecular characterization of acute myeloid leukemia
Haematologica, July 1, 2008; 93(7): 976 - 982.
[Full Text] [PDF]

Home page
 haematolHome page
W. Blum
Post-remission therapy in acute myeloid leukemia: what should I do now?
Haematologica, June 1, 2008; 93(6): 801 - 805.
[Full Text] [PDF]

Home page
 BloodHome page
C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrozek, C. D. Baldus, T. Vukosavljevic, C.-G. Liu, M. E. Ross, et al.
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Blood, June 1, 2008; 111(11): 5371 - 5379.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, et al.
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
N. Engl. J. Med., May 1, 2008; 358(18): 1909 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al.
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Blood, May 1, 2008; 111(9): 4797 - 4808.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Bullinger, K. Dohner, R. Kranz, C. Stirner, S. Frohling, C. Scholl, Y. H. Kim, R. F. Schlenk, R. Tibshirani, H. Dohner, et al.
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Blood, May 1, 2008; 111(9): 4490 - 4495.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. Tyybakinoja, E. Elonen, H. Vauhkonen, J. Saarela, and S. Knuutila
Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity
Haematologica, April 1, 2008; 93(4): 631 - 632.
[Full Text] [PDF]

Home page
 BloodHome page
R. E. Gale, C. Green, C. Allen, A. J. Mead, A. K. Burnett, R. K. Hills, D. C. Linch, and on behalf of the Medical Research Council Adult Le
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Blood, March 1, 2008; 111(5): 2776 - 2784.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. Y. Kim, H.-J. Song, H.-J. Lim, M.-G. Shin, J. S. Kim, H.-J. Kim, B. Y. Kim, and S.-w. Lee
Platelet Factor-4 Is an Indicator of Blood Count Recovery in Acute Myeloid Leukemia Patients in Complete Remission
Mol. Cell. Proteomics, February 1, 2008; 7(2): 431 - 441.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Whitman, A. S. Ruppert, M. D. Radmacher, K. Mrozek, P. Paschka, C. Langer, C. D. Baldus, J. Wen, F. Racke, B. L. Powell, et al.
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Blood, February 1, 2008; 111(3): 1552 - 1559.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport, M. S. Brose, A. Medina, R. Letrero, M. Herlyn, and R. H. Edwards
Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma
J. Mol. Diagn., September 1, 2007; 9(4): 464 - 471.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Vempati, C. Reindl, S. K. Kaza, R. Kern, T. Malamoussi, M. Dugas, G. Mellert, S. Schnittger, W. Hiddemann, and K. Spiekermann
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential
Blood, July 15, 2007; 110(2): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood, January 15, 2007; 109(2): 431 - 448.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
H. Dohner
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 412 - 419.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Marzac, I. Teyssandier, O. Calendini, J.-Y. Perrot, A.-M. Faussat, R. Tang, N. Casadevall, J.-P. Marie, and O. Legrand
Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia
Clin. Cancer Res., December 1, 2006; 12(23): 7018 - 7024.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. DeAngelo, R. M. Stone, M. L. Heaney, S. D. Nimer, R. L. Paquette, R. B. Klisovic, M. A. Caligiuri, M. R. Cooper, J.-M. Lecerf, M. D. Karol, et al.
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Blood, December 1, 2006; 108(12): 3674 - 3681.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Knapper, K. I. Mills, A. F. Gilkes, S. J. Austin, V. Walsh, and A. K. Burnett
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Blood, November 15, 2006; 108(10): 3494 - 3503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. A. Pollard, T. A. Alonzo, R. B. Gerbing, W. G. Woods, B. J. Lange, D. A. Sweetser, J. P. Radich, I. D. Bernstein, and S. Meshinchi
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia
Blood, October 15, 2006; 108(8): 2764 - 2769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. D. Radmacher, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, J. W. Vardiman, P. Paschka, T. Vukosavljevic, C. D. Baldus, J. E. Kolitz, et al.
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
Blood, September 1, 2006; 108(5): 1677 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. S. Farag, K. J. Archer, K. Mrozek, A. S. Ruppert, A. J. Carroll, J. W. Vardiman, M. J. Pettenati, M. R. Baer, M. B. Qumsiyeh, P. R. Koduru, et al.
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Blood, July 1, 2006; 108(1): 63 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. D. Bloomfield, K. Mrozek, and M. A. Caligiuri
Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions.
Clin. Cancer Res., June 1, 2006; 12(11): 3564s - 3571s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Thiede, S. Koch, E. Creutzig, C. Steudel, T. Illmer, M. Schaich, G. Ehninger, and for the Deutsche Studieninitiative Leukamie (DSIL)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
Blood, May 15, 2006; 107(10): 4011 - 4020.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, J. H. Engel, E. L. Pogosova-Agadjanyan, J. Linsley, M. L. Slovak, C. L. Willman, and J. P. Radich
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
Blood, May 1, 2006; 107(9): 3724 - 3726.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Zeng, I. J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, D. Harris, O. Frolova, N. Hail Jr., W. Chen, S. M. Kornblau, et al.
Simultaneous Inhibition of PDK1/AKT and Fms-Like Tyrosine Kinase 3 Signaling by a Small-Molecule KP372-1 Induces Mitochondrial Dysfunction and Apoptosis in Acute Myelogenous Leukemia.
Cancer Res., April 1, 2006; 66(7): 3737 - 3746.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
H. S. Radomska, D. S. Basseres, R. Zheng, P. Zhang, T. Dayaram, Y. Yamamoto, D. W. Sternberg, N. Lokker, N. A. Giese, S. K. Bohlander, et al.
Block of C/EBP{alpha} function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
J. Exp. Med., February 21, 2006; 203(2): 371 - 381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. D. Baldus, C. Thiede, S. Soucek, C. D. Bloomfield, E. Thiel, and G. Ehninger
BAALC Expression and FLT3 Internal Tandem Duplication Mutations in Acute Myeloid Leukemia Patients With Normal Cytogenetics: Prognostic Implications
J. Clin. Oncol., February 10, 2006; 24(5): 790 - 797.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Marcucci, C. D. Baldus, A. S. Ruppert, M. D. Radmacher, K. Mrozek, S. P. Whitman, J. E. Kolitz, C. G. Edwards, J. W. Vardiman, B. L. Powell, et al.
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., December 20, 2005; 23(36): 9234 - 9242.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Dohner, R. F. Schlenk, M. Habdank, C. Scholl, F. G. Rucker, A. Corbacioglu, L. Bullinger, S. Frohling, H. Dohner, and for the AML Study Group (AMLSG)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Blood, December 1, 2005; 106(12): 3740 - 3746.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. E. Gale, R. Hills, P. D. Kottaridis, S. Srirangan, K. Wheatley, A. K. Burnett, and D. C. Linch
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
Blood, November 15, 2005; 106(10): 3658 - 3665.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. H. Brandts, B. Sargin, M. Rode, C. Biermann, B. Lindtner, J. Schwable, H. Buerger, C. Muller-Tidow, C. Choudhary, M. McMahon, et al.
Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation
Cancer Res., November 1, 2005; 65(21): 9643 - 9650.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Fitzgibbon, L.-L. Smith, M. Raghavan, M. L. Smith, S. Debernardi, S. Skoulakis, D. Lillington, T. A. Lister, and B. D. Young
Association between Acquired Uniparental Disomy and Homozygous Gene Mutation in Acute Myeloid Leukemias
Cancer Res., October 15, 2005; 65(20): 9152 - 9154.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Yang, L. Liu, D. Sternberg, L. Tang, I. Galinsky, D. DeAngelo, and R. Stone
The FLT3 Internal Tandem Duplication Mutation Prevents Apoptosis in Interleukin-3-Deprived BaF3 Cells Due to Protein Kinase A and Ribosomal S6 Kinase 1-Mediated BAD Phosphorylation at Serine 112
Cancer Res., August 15, 2005; 65(16): 7338 - 7347.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Levis, K. M. Murphy, R. Pham, K.-T. Kim, A. Stine, L. Li, I. McNiece, B. D. Smith, and D. Small
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
Blood, July 15, 2005; 106(2): 673 - 680.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Whitman, S. Liu, T. Vukosavljevic, L. J. Rush, L. Yu, C. Liu, M. I. Klisovic, K. Maharry, M. Guimond, M. P. Strout, et al.
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
Blood, July 1, 2005; 106(1): 345 - 352.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Bagrintseva, S. Geisenhof, R. Kern, S. Eichenlaub, C. Reindl, J. W. Ellwart, W. Hiddemann, and K. Spiekermann
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
Blood, May 1, 2005; 105(9): 3679 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Wolfler, S. J. Erkeland, C. Bodner, M. Valkhof, W. Renner, C. Leitner, W. Olipitz, M. Pfeilstocker, C. Tinchon, W. Emberger, et al.
A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome
Blood, May 1, 2005; 105(9): 3731 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Farag, A. S. Ruppert, K. Mrozek, R. J. Mayer, R. M. Stone, A. J. Carroll, B. L. Powell, J. O. Moore, M. J. Pettenati, P. R.K. Koduru, et al.
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol., January 20, 2005; 23(3): 482 - 493.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood, January 1, 2005; 105(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. W. H. Yee, M. Schittenhelm, A.-M. O'Farrell, A. R. Town, L. McGreevey, T. Bainbridge, J. M. Cherrington, and M. C. Heinrich
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
Blood, December 15, 2004; 104(13): 4202 - 4209.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. J. Lacayo, S. Meshinchi, P. Kinnunen, R. Yu, Y. Wang, C. M. Stuber, L. Douglas, R. Wahab, D. L. Becton, H. Weinstein, et al.
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
Blood, November 1, 2004; 104(9): 2646 - 2654.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. J. Clark, J. Cools, D. P. Curley, J.-C. Yu, N. A. Lokker, N. A. Giese, and D. G. Gilliland
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
Blood, November 1, 2004; 104(9): 2867 - 2872.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Brown, S. Meshinchi, M. Levis, T. A. Alonzo, R. Gerbing, B. Lange, R. Arceci, and D. Small
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
Blood, September 15, 2004; 104(6): 1841 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. H. Min, J.-W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee
Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia
Cancer Res., August 1, 2004; 64(15): 5225 - 5231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne
Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs
Clin. Chem., July 1, 2004; 50(7): 1165 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Grever
Pharmacodynamics provide critical insight in drug development
Blood, May 15, 2004; 103(10): 3614 - 3614.
[Full Text] [PDF]

Home page
 BloodHome page
B. D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K. M. Murphy, T. Dauses, J. Allebach, and D. Small
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Blood, May 15, 2004; 103(10): 3669 - 3676.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Bagrintseva, R. Schwab, T. M. Kohl, S. Schnittger, S. Eichenlaub, J. W. Ellwart, W. Hiddemann, and K. Spiekermann
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
Blood, March 15, 2004; 103(6): 2266 - 2275.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Ozeki, H. Kiyoi, Y. Hirose, M. Iwai, M. Ninomiya, Y. Kodera, S. Miyawaki, K. Kuriyama, C. Shimazaki, H. Akiyama, et al.
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
Blood, March 1, 2004; 103(5): 1901 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, R. F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
J. Clin. Oncol., February 15, 2004; 22(4): 624 - 633.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Perrotti, G. Marcucci, and M. A. Caligiuri
Loss of C/EBP{alpha} and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
J. Clin. Oncol., February 15, 2004; 22(4): 582 - 584.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-Y. Shih, C.-F. Huang, J.-H. Wu, P.-N. Wang, T.-L. Lin, P. Dunn, M.-C. Chou, M.-C. Kuo, and C.-C. Tang
Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia: A Comparative Analysis of 120 Paired Diagnostic and Relapse Bone Marrow Samples
Clin. Cancer Res., February 15, 2004; 10(4): 1326 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
J. Clin. Oncol., December 15, 2003; 21(24): 4642 - 4649.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Minami, K. Yamamoto, H. Kiyoi, R. Ueda, H. Saito, and T. Naoe
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia
Blood, October 15, 2003; 102(8): 2969 - 2975.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
Blood, October 1, 2003; 102(7): 2387 - 2394.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. D. Baldus, S. M. Tanner, A. S. Ruppert, S. P. Whitman, K. J. Archer, G. Marcucci, M. A. Caligiuri, A. J. Carroll, J. W. Vardiman, B. L. Powell, et al.
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
Blood, September 1, 2003; 102(5): 1613 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Spiekermann, K. Bagrintseva, R. Schwab, K. Schmieja, and W. Hiddemann
Overexpression and Constitutive Activation of FLT3 Induces STAT5 Activation in Primary Acute Myeloid Leukemia Blast Cells
Clin. Cancer Res., June 1, 2003; 9(6): 2140 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
K. M. Murphy, M. Levis, M. J. Hafez, T. Geiger, L. C. Cooper, B.D. Smith, D. Small, and K. D. Berg
Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay
J. Mol. Diagn., May 1, 2003; 5(2): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Bohmer, et al.
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
Blood, April 15, 2003; 101(8): 3164 - 3173.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Spiekermann, R. J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske, S. Schnittger, L. M. Kelly, D. G. Gilliland, and W. Hiddemann
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
Blood, February 15, 2003; 101(4): 1494 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
B. Lowenberg, J. D. Griffin, and M. S. Tallman
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Hematology, January 1, 2003; 2003(1): 82 - 101.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, K. Mrozek, R. K. Dodge, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, S. R. Patil, K. W. Rao, M. S. Watson, et al.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Blood, December 15, 2002; 100(13): 4325 - 4336.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Frohling, R. F. Schlenk, J. Breitruck, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Blood, December 15, 2002; 100(13): 4372 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Spiekermann, K. Bagrintseva, C. Schoch, T. Haferlach, W. Hiddemann, and S. Schnittger
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
Blood, October 16, 2002; 100(9): 3423 - 3425.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. W. H. Yee, A. M. O'Farrell, B. D. Smolich, J. M. Cherrington, G. McMahon, C. L. Wait, L. S. McGreevey, D. J. Griffith, and M. C. Heinrich
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
Blood, September 26, 2002; 100(8): 2941 - 2949.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L.-Y. Shih, C.-F. Huang, J.-H. Wu, T.-L. Lin, P. Dunn, P.-N. Wang, M.-C. Kuo, C.-L. Lai, and H.-C. Hsu
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
Blood, September 18, 2002; 100(7): 2387 - 2392.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. G. Gilliland and J. D. Griffin
The roles of FLT3 in hematopoiesis and leukemia
Blood, August 13, 2002; 100(5): 1532 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Schnittger, C. Schoch, M. Dugas, W. Kern, P. Staib, C. Wuchter, H. Loffler, C. M. Sauerland, H. Serve, T. Buchner, et al.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
Blood, June 17, 2002; 100(1): 59 - 66.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Thiede, C. Steudel, B. Mohr, M. Schaich, U. Schakel, U. Platzbecker, M. Wermke, M. Bornhauser, M. Ritter, A. Neubauer, et al.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Blood, May 29, 2002; 99(12): 4326 - 4335.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Schilsky, L. M. Dressler, D. Bucci, L. Monovich, S. Jewell, S. Suster, M. A. Caligiuri, P. W. Kantoff, and C. Compton
Cooperative Group Tissue Banks As Research Resources: The Cancer and Leukemia Group B Tissue Repositories
Clin. Cancer Res., May 1, 2002; 8(5): 943 - 948.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology, January 1, 2002; 2002(1): 73 - 110.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.